OrbiMed Advisors CRNX Position
Active11-Fund ConvergenceOrbiMed Advisors trimmed their position in Crinetics Pharmaceuticals Inc. (CRNX) in Q4 2025, holding $46.5M worth of shares across 999,000 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
CRNX is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for atumelnant in 198 days (Oct 31, 2026), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 16.5% of float with 15.3 days to cover, indicating significant bearish positioning against OrbiMed's long thesis.
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Full company profile →Short Interest
16.5%
15.3 days to cover
OrbiMed Advisors CRNX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 999,000 | -100,000 | $46.5M |
| Q3 2025 | Decreased | 1,099,000 | -50,000 | $45.8M |
| Q2 2025 | Increased | 1,149,000 | +150,000 | $33.0M |
| Q1 2025 | Held | 999,000 | — | $33.5M |
| Q4 2024 | Decreased | 999,000 | -51,055 | $51.1M |
| Q3 2024 | Decreased | 1,050,055 | -230,745 | $53.7M |
| Q2 2024 | Decreased | 1,280,800 | -104,200 | $57.4M |
| Q1 2024 | Decreased | 1,385,000 | -282,360 | $64.8M |
| Q4 2023 | Decreased | 1,667,360 | -1,228,714 | $59.3M |
| Q3 2023 | Decreased | 2,896,074 | -1,054,722 | $86.1M |
| Q2 2023 | Held | 3,950,796 | — | $71.2M |
| Q1 2023 | New | 3,950,796 | +3,950,796 | $63.5M |
Frequently Asked Questions
Does OrbiMed Advisors own CRNX?
Yes. As of Q4 2025, OrbiMed Advisors holds 999,000 shares of Crinetics Pharmaceuticals Inc. (CRNX) valued at $46.5M. This data comes from their SEC 13F filing.
How many hedge funds own CRNX?
11 specialist biotech hedge funds currently hold CRNX, including Driehaus Capital, EcoR1 Capital, Baker Bros. Advisors and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CRNX?
OrbiMed Advisors's position in CRNX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CRNX position increasing or decreasing?
OrbiMed Advisors trimmed their CRNX position in the most recent quarter, reducing by 100,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CRNXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →